Conversely, overexpression of EHF drives HER2 expression in gastric and thyroid cancers, sensitizing these tumours to HER2 inhibition, while in lung cancer cell lines, ELF3 overexpression activates the PI3K/AKT and MAPK pathways and sensitized lung cancer cells to inhibitors of these pathways [43]. Here, ELF3 is linked to lung carcinoma.